Cardiomyopathies in disorders of oxidative metabolism

Cardiovascular Research

Volumn 35, Issue 2, 1997, Pages 184-199

  Antozzi, Carlo ^a   Zeviani, Massimo ^b,c,d  

^a Neuromuscular Research Department   (Italy)

^b Children's Hosp Bambino Gesù ^*  (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Oxidation; Cardiomyopathy; Mitochondrial DNA; Oxidative metabolism; Respiratory chain

Indexed keywords

MITOCHONDRIAL DNA;

AEROBIC METABOLISM; CARDIOMYOPATHY; DISEASE CLASSIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; FATTY ACID OXIDATION; HEART CONTRACTION; HUMAN; HUMAN CELL; MOLECULAR GENETICS; OXIDATIVE PHOSPHORYLATION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEFECT; REVIEW;

CARDIOMYOPATHIES; DNA, MITOCHONDRIAL; GENE REARRANGEMENT; HUMANS; LIPID METABOLISM; MITOCHONDRIA, HEART; OXIDATIVE PHOSPHORYLATION; POINT MUTATION;

EID: 0030820508     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00141-7     Document Type: Review

References (176)

1. Layzer RB. How muscle uses fuel. New Engl J Med 1991;324:411.
2. McArdle WD, Katch FI, Katch VL. The cardiovascular system. In: Exercise physiology. Energy, nutrition and human performance. Philadelphia: Lea and Febiger, 1991:292-312.
3. Kelly DP, Strauss AW. Inherited cardiomyopathies. N Engl J Med 1994;330:913-919.
4. Schwartz ML, Cox GF, Lin AE, et al. Clinical approach to genetic cardiomyopathy in children. Circulation 1996;94:2021-2022.
5. Servidei S, Bertini E, Di Mauro S. Hereditary metabolic cardiomyopathies. Adv Pediatr 1994;41:1-32.
6. Tzagoloff A. Mitochondria. Sikievitz P, editor. New York: Plenum Press, 1982.
7. Anderson S, Bankier AT, Barrel BG, et al. Sequence and organization of the human mitochondrial genome. Nature 1981;290:457-465.
8. Zeviani M, Antozzi C. Defects of mitochodrial DNA. Brain Pathol 1992;2:121-132.
9. DiMauro S, Moraes CT. Mitochondrial encephalomyopathies. Arch Neurol 1993;50:1197-1208.
10. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331:717-719.
11. Zeviani M, Moraes CT, Di Mauro S, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988;38:1339-1346.
12. Poulton J. Duplications of mitochondrial DNA: implications for pathogenesis. J Inher Metab Dis 1992;15:487-498.
13. Rötig A, Cormier V, Blache S, et al. Pearson's marrow-pancreas syndrome. A multisystem mitochondrial disorder of infancy. J Clin Invest 1990;86:1601-1608.
14. Roberts NK, Perloff JK, Kark RAP. Cardiac conduction in the Kearns-Sayre syndrome (a neuromuscular disorder associated with progressive external ophthalmoplegia and pigmentary retinopathy). Am J Cardiol 1979;44:1396-1400.
15. Channer KS, Channer JL, Campbell MJ, Russel Rees J. Cardiomyopathy in the Kearns-Sayre syndrome. Br Heart J 1988;59:486-490.
16. Kleber FX, Park JW, Hubner G, Johannes A, Pongratz D, Konig E. Congestive heart failure due to mitochondrial cardiomyopathy in Kearns-Sayre syndrome. Klin Wochenschr 1987;35:480-486.
17. Tveskov C, Angelo-Nielsen K. Kearns-Sayre and dilated cardiomyopathy. Neurology 1990;40:553-554.
18. Kosinski C, Mull M, Lethern H, Töpper R. Evidence for cardioembolic stroke in a case of Kearns-Sayre syndrome. Stroke 1995;26:1950-1952.
19. Remes AM, Hassinen IE, Majama A, Peuhkurinen KJ. Mitochondrial DNA deletion diagnosed by analysis of endomyocardial biopsy specimen from a patient with Kearns-Sayre syndrome and complete heart block. Br Heart J 1992;68:408-411.
20. Muller-Hocker J, Seibel P, Schneiderbanger K, et al. In situ hybridization of mitochondrial DNA in the heart of a patient with Kearns-Sayre syndrome and dilatative cardiomyopathy. Hum Pathol 1992;23:1431-1437.
21. Shanske S, Moraes CT, Lombes A, et al. Widespread tissue distribution and transmission of mitochondrial DNA deletions in Kearns-Sayre syndrome. Neurology 1990;40:24-28.
22. Zeviani M, Gellera C, Pannacci M, et al. Tissue distribution and transmission of mitochondrial DNA deletions in mitochondrial myopathies. Ann Neurol 1990;28:94-97.
23. Moraes CT, Di Mauro S, Zeviani M, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med 1989;320:1293-1299.
24. Schon EA, Rizzuto R, Moraes CT, Nakase H, Zeviani M, Di Mauro S. A direct repeat is a hot spot for large-scale deletions of human mitochondrial DNA. Science 1989;244:346-349.
25. Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip replication model and metabolic therapy. Proc Natl Acad Sci USA 1989;86:7952-7856.
26. Mita S, Schmidt B, Schon EA, Di Mauro S, Bonilla E. Detection of deleted mitochondrial genomes in cytochrome c oxidase-deficient muscle fibers of a patient with Kearns-Sayre syndrome. Proc Natl Acad Sci USA 1989;86:9509-9513.
27. Shoubridge EA, Karpati G, Hastings KEM. Deletion mutants are functionally dominant over wild-type mitochondrial genomes in skeletal muscle fiber segments in mitochondrial diseases. Cell 1990;62:43-49.
28. Hayashi JI, Ohta S, Kikuchi A, Takemitsu M, Goto YI, Nonaka I. Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction. Proc Natl Acad Sci USA 1991;88:10614-10618.
29. Leu(UUR) an etiologic hot spot?. J Clin Invest 1993;92:2906-2915.
30. Leu(UUR) gene associated with MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990;348:651-653.
31. Hirano M, Ricci E, Koenigsberger R, et al. MELAS: an original case and clinical criteria for diagnosis. Neuromusc Disord 1992;2:125-135.
32. Ciafaloni E, Ricci E, Shanske S, et al. MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol 1992:31:391-398.
33. Reardon W, Ross RJM, Sweeney MG, et al. Diabetes mellitus associated with a pathogenic point mutation in mtDNA. Lancet 1992;340:1376-1379.
34. (3243) mutation. A clinical and genetic study. Brain 1995;118:721-734.
35. Sweeney MG, Bundey S, Brockington M, Poulton K, Winer JB, Harding AE. A mitochondrial myopathy associated with sudden death in young adults and a novel mutation in the mitochondrial DNA leucine transfer RNA(UUR) gene. Q J Med 1993;86:709-713.
36. Morten KJ, Cooper JM, Brown GK, Lake BD, Pike D, Poulton J. A new point mutation associated with mitochondrial encephalomyopathy. Hum Mol Genet 1993;2:2081-2087.
37. Goto Y, Nonaka I, Horai S. A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes. Biochim Biophys Acta 1991;1097:238-240.
38. Leu(UUR) gene in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Biochem Biophys Res Commun 1994;202:1624-1630.
39. Manfredi G, Schon EA, Moraes CT, et al. A new mutation associated with MELAS is located in a mitochondrial DNA polypeptide-coding gene. Neuromusc Dis 1995;5:391-398.
40. Taylor RW, Chinnery PF, Haldane F, et al. MELAS associated with a mutation in the valine transfer RNA gene of mitochondrial DNA. Ann Neurol 1996;40:459-462.
41. Yoneda M, Tanaka M, Nishikimi M, et al. Pleiotropic molecular defects in energy-transducing complexes in mitochondrial encephalomyopathy (MELAS). J Neurol Sci 1989;92:143-158.
42. Fujii T, Okuno T, Ito M, et al. MELAS of infantile onset: mitochondrial angiopathy or cytopathy. J Neurol Sci 1991;103:37-41.
43. Obayashi T, Hattori K, Sugiyama S, et al. Point mutations in mitochondrial DNA in patients with hypertrophic cardiomyopathy. Am Heart J 1992;124:1263-1269.
44. Damian HA, Seibel P, Reichmann H, et al. Clinical spectrum of the MELAS mutation in a large pedigree. Acta Neurol Scand 1995;92:409-415.
45. Manouvrier S, Rötig A, Hannebique G, et al. Point mutation in the maternally inherited hypertrophic cardiomyopathy, diabetes mellitus, renal failure, and sensorineural deafness. J Med Genet 1995;32:654-656.
46. Suzuki S, Harada K, Miura Y, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS): decrease in diastolic left ventricular function assessed by echocardiography. Pediatr Cardiol 1993;14:162-166.
47. Sakuta R, Nonaka I. Vascular involvement in mitochondrial myopathy. Ann Neurol 1989;25:597-601.
48. Ohama E, Ohara S, Tanaka K. Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta Neuropathol (Berl) 1987;74:226-233.
49. Hasegawa H, Matsuoka T, Goto Y, Nonaka I. Strongly succinate dehydrogenase-reactive blood vessels in muscles from patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Ann Neurol 1991;29:601-605.
50. Sato W, Tanaka M, Sugiyama S, et al. Cardiomyopathy and angiopathy in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episodes. Am Heart J 1994;128:733-741.
51. Leu(UUR). Lancet 1991;338:143-147.
52. Sweeney MG, Brockington M, Weston MJ, Morgan-Hughes JA, Harding AE. Mitochondrial DNA transfer mutation Leu(UUR)A → G 3260: a second family with myopathy and cardiomyopathy. Q J Med 1993;86:435-438.
53. Nishino I, Komatsu M, Kodama S, Horai S, Nonaka I, Goto Y. The 3260 mutation in mitochondrial DNA can cause mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Muscle Nerve 1996;19:1603-1604.
54. King M, Attardi G. Human cells lacking mitochondrial DNA: repopulation with exogenous mitochondria by complementation. Science 1989;246:500-503.
55. Mariotti C, Tiranti V, Carrara F, Dallapiccola B, DiDonato S, Zeviani M. Defective respiratory capacity and mitochondrial proLeu(UUR) tein synthesis in transformant cybrids harboring the tRNAleu(UUR) mutation associated with maternally inherited myopathy and cardiopathy. J Clin Invest 1994;93:1102-1107.
56. Silvestri G, Santorelli S, Shanske S, et al. A new mtDNA mutation in the tRNALeu(UUR) gene associated with maternally inherited cardiomyopathy. Hum Mutat 1994;3:37-43.
57. Ile mutation in fatal cardiomyopathy. Biochem Biophys Res Commun 1992;186:47-53.
58. Ile 4269 mutation): histochemical, immunohistochemical, and ultrastructural study. J Neurol Sci 1995;131:170-176.
59. Hayashi J-I, Ohta S, Kagawa Y, et al. Functional and morphological abnormalities of mitochondria in human cells containing mitochondrial DNA with pathogenic point mutations in tRNA genes. J Biol Chem 1994;22:19060-19066.
60. Casali C, Santorelli FM, D'Amati G, Bernucci P, DeBiase L, DiMauro S. A novel mtDNA point mutation in maternally inherited cardiomyopathy. Biochem Biophys Res Commun 1995;213:588-593.
61. Tanaka M, Ino H, Ohno K, et al. Mitochondrial mutation in fatal infantile cardiomyopathy. Lancet 1990;336:1452.
62. Santorelli FM, Mak SC, Vazques-Acevedo M, et al. A novel pathogenic mitochondrial DNA point mutation associated with mitochondrial encephalocardiomyopathy. Biochem Biophys Res Commun 1995;216:835-840.
63. Wallace DC, Zeng X, Lott MT, et al. Familial mitochondrial encephalomyopathies (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell 1988;55:601-610.
64. Lys mutation. Cell 1990;61:931-937.
65. Silvestri G, Moraes CT, Shanske S, Oh SJ, DiMauro S. A new mtDNA mutation in the tRNALys gene associated with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 1992;51:1213-1217.
66. Lys gene. Eur J Hum Genet 1993;1:80-87.
67. Ser(UCN) gene detected in a family with MERRF/MELAS overlap syndrome. Biochem Biophys Res Commun 1995;214:86-93.
68. Lombes A, Mendell JR, Nakase H, et al. Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology, biochemistry, and molecular genetics. Ann Neurol 1989;26:20-33.
69. Lys gene (G8363A). Am J Hum Genet 1996;58:933-939.
70. Gly gene. Am J Hum Genet 1994;55:437-446.
71. Holt IJ, Harding AE, Petty RHK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J hum Genet 1990;46:428-433.
72. de Vries DD, van Engelen BGM, Gabreels FJM, Ruitenbeek W, van Oost BA. A second missense mutation in mitochondrial ATPase 6 gene in Leigh syndrome. Ann Neurol 1993;34:410-412.
73. Tatuch Y, Christodoulou J, Feigenbaum A, et al. Heteroplasmic mtDNA mutation (T → G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high. Am J Hum Genet 1992;50:852-858.
74. Van Coster R, Lombes A, DeVivo DC, et al. Cytochrome c oxidase-associated Leigh syndrome: phenotypic features and pathogenetic speculations. J Neurol Sci 1991;104:97-111.
75. Rahman S, Blok RB, Dahl HH, et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol 1996;39:343-351.
76. Tatuch Y, Robinson BH. The mitochondrial DNA mutation at 8993 associated with NARP slows the rate of ATP synthesis in isolated lymphoblast mitochondria. Biochem Biophys Res Commun 1993;144:124-128.
77. Houstek J, Klement P, Hermanska J, et al. Altered properties of mitochondrial ATP-synthase in patients with a T → G mutation in the ATPase (subunit 6) gene at position 8993. Biochim Biophys Acta 1995;1271:349-357.
78. Rutledge JC, Haas JE, Monnat R, Milstein JM. Hypertrophic cardiomyopathy is a component of subacute necrotizing encephalomyelopathy. J Pediatr 1982;101:706-710.
79. Pastores GM, Santorelli FM, Shanske S, et al. Leigh syndrome and hypertrophic cardiomyopathy in an infant with a mitochondrial DNA point mutation (T8993G). Am J Med Genet 1994;50:265-271.
80. Riordan-Eva P, Sanders MD, Govan GG, Sweeney MG, DaCosta J, Harding AE. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. Brain 1995;118:319-337.
81. Nikoskelainen EK, Savontaus ML, Huoponen K, Antila K, Hartiala J. Pre-excitation syndrome in Leber's hereditary optic neuropathy. Lancet 1994;344:857-858.
82. Chomyn A, Martinuzzi A, Yoneda M, et al. The MELAS-associated mutations in the mtDNA binding site for the transcription termination factor cause protein synthesis and respiration defects, but do not affect the levels of upstream and downstream mature transcripts. Proc Natl Acad Sci USA 1992;89:4221-4225.
83. King P, Koga Y, Davidson M, Schon EA. Defects in mitochondrial protein synthesis and respiratory chain activity segregate with the tRNALeu(UUR) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episodes. Mol Cell Biol 1992;12:480-490.
84. Enriquez JA, Chomyn A, Attardi G. MtDNA mutation in MERRF syndrome causes defective aminoacylation of tRNALys and premature translation termination. Nature Genet 1995;10:47-55.
85. Zeviani M, Servidei S, Gellera C, Bertini E, DiMauro S, DiDonato S. An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature 1989;339:309-311.
86. Suomalainen A, Paetau A, Leinonen H, Majander A, Peltonen L, Somer H. Inherited idiopathic dilated cardiomyopathy with multiple deletions of mitochondrial DNA. Lancet 1992;340:1349-1320.
87. Takei Y, Ikeda S, Yanagisawa N, Takahashi W, Sekiguchi M, Hayashi T. Multiple mitochondrial DNA deletions in a patient with mitochondrial myopathy and cardiomyopathy but no ophthalmoplegia. Muscle Nerve 1995;18:1321-1325.
88. Bohlega S, Tanji K, Santorelli FM, Hirano M, al-Jishi A, DiMauro S. Multiple mitochondrial DNA deletions associated with autosomal recessive ophthalmoplegia and severe cardiomyopathy. Neurology 1996;46:1329-1334.
89. Bourgeron T, Rustin P, Chretien D, et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet 1995;11:144-149.
90. Guenthard J, Wyler F, Fowler B, Baumgartner R. Cardiomyopathy in respiratory chain disorders. Arch Dis Child 1995;72:223-226.
91. Moreadith RM, Batshaw ML, Ohnishi T, et al. Deficiency of the iron-sulfur clusters of mitochondrial reduced nicotinamide-adenine dinucleotide-ubiquinone oxidoreductase (complex I) in an infant with congenital lactic acidosis. J Clin Invest 1984;74:684-697.
92. Robinson BH, Ward J, Goodyer P, Beaudet P. Respiratory chain defects in the mitochondria of cultured skin fibroblasts from three patients with lacticacidemia. J Clin Invest 1986;77:1422-1427.
93. Hoppel CL, Kerr DS, Dahms B, Roessmann U. Deficiency of the reduced nicotinamide adenine dinucleotide dehydrogenase component of complex I of mitochondrial electron transport. J Clin Invest 1987;80:71-77.
94. Papadimitriou A, Neustein HB, Di Mauro S, Stanton R, Bresolin N. Histiocytoid cardiomyopathy of infancy: deficiency of reducible cytochrome b in heart mitochondria. Pediatr Res 1984;18:1023-1028.
95. Rimoldi M, Bottacchi E, Rossi L, Cornelio F, Uziel G, DiDonato S. Cytochrome c oxidase deficiency in muscles of a floppy infant without mitochondrial myopathy. J Neurol 1982;227:201-207.
96. Zeviani M, Van Dyke DH, Servidei S, et al. Myopathy and fatal cardiopathy due to cytochrome c oxidase deficiency. Arch Neurol 1986;43:1198-1202.
97. Kennaway NG, Carrero-Venezuela RD, Ewart G, et al. Isoforms of mammalian cytochrome c oxidase: correlation with human cytochrome c oxidase deficiency. Pediatr Res 1990;28:529-535.
98. Holme E, Greter J, Jacobson CE, et al. Mitochondrial ATP-synthase deficiency in a child with 3-methylglutaconic aciduria. Pediatr Res 1992;32:731-735.
99. Ibel H, Endres W, Hadorn HB, et al. Multiple respiratory chain abnormalities associated with hypertrophic cardiomyopathy and 3-methylglutaconic aciduria. Eur J Pediatr 1993;152:665-670.
100. Korenke GC, Bentlage HACM, Ruitenbeck W. Isolated and combined deficiencies of NADH dehydrogenase (complex I) in muscle tissue of children with mitochondrial myopathies. Eur J Pediatr 1990;150:104-108.
101. 3 in muscle from a floppy infant with cytochrome c oxidase deficiency. Eur J Pediatr 1984;141:178-180.
102. Muller-Hocker J, Ibel H, Paetzke I, et al. Fatal infantile mitochondrial cardiomyopathy and myopathy with heterogeneous tissue expression of combined respiratory chain defects. Virchows Arch [A] 1991;419:355-362.
103. Sengers RCA, Ter Haar EGA, Trijbels JMF, Willems JH, Daniels O, Stadhouders AM. Congenital cataract and mitochondrial myopathy of skeletal and heart muscle associated with lactic acidosis after exercise. J Pediatr 1975;86:873-880.
104. Sengers RCA, Stadhouders AM, Van Lakwijk-Vondrovicova E, Kubat K, Ruitenbeek W. Hypertrophic cardiomyopathy associated with a mitochondrial myopathy of voluntary muscles and congenital cataract. Br Heart J 1985;54:543-547.
105. Smeitink JAM, Sengers RCA, Trijbels JMF, et al. Fatal neonatal cardiomyopathy associated with cataract and mitochondrial myopathy. Eur J Pediatr 1989;148:656-659.
106. Romero NB, Marsac C, Paturneau-Jouas M, Ogier H, Magnier S, Fardeau M. Infantile familial cardiomyopathy due to mitochondrial complex I and IV associated deficiency. Neuromusc Dis 1993;3:31-42.
107. Van Hove JLK, Shanske S, Ciacci F, et al. Mitochondrial myopathy with anemia, cardiomyopathy, lactic acidosis: a distinct late onset mitochondrial disorder. Am J Hum Genet 1994;51:114-120.
108. Marin-Garcia J, Goldenthal MJ. Mitochondrial cardiomyopathy. Pediatr Cardiol 1995;16:28-30.
109. Rustin P, Lebidos J, Chretien D, et al. Endomyocardial biopsies for early detection of mitochondrial disorders in hypertrophic cardiomyopathies. J Pediatr 1994;124:224-228.
110. Luft R. The development of mitochondrial medicine. Proc Natl Acad Sci USA 1994;91:8731-8738.
111. Li Y, Huang T-T, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995;11:376-381.
112. Schapira AHV. Mitochondrial dysfunction in neurodegenerative disorders and aging. In: Schapira AHV, Di Mauro S, editors. Mitochondrial disorders in Neurology. Oxford: Butterworth-Heinemann, 1994:227-244.
113. Trounce I, Byrne E, Marzuki S. Decline in skeletal muscle mitochondrial respiratory chain function, possible factor in ageing. Lancet 1989;i:637-639.
114. Cortopassi GA, Shibata D, Soong NW, Arnheim N. A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. Proc Natl Acad Sci USA 1992;89:7370-7374.
115. Hattori K, Tanaka M, Sugiyama S, et al. Age-dependent increase in deleted mitochondrial DNA in the human heart: possible contributory factor to presbycardia. Am Heart J 1991;121:1735-1742.
116. Maurer I, Zierz S. Myocardial respiratory chain enzyme activities in idiopathic dilated cardiomyopathy, and comparison with those in atherosclerotic coronary artery disease and valvular aortic stenosis. Am J Cardiol 1993;72:428-433.
117. Li YY, Hengstenberg C, Maisch B. Whole mitochondrial genome amplification reveals basal level multiple deletions in mtDNA in patients with dilated cardiomyopathy. Biochem Biophys Res Commun 1995;210:211-218.
118. Di Donato S. Disorders of lipid metabolism affecting skeletal muscle: carnitine deficiency syndromes, defects in the catabolic pathway, and Chanarin disease. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill, 1994:1587-1609.
119. Pollit RJ. Disorders of mitochondrial long-chain fatty acid oxidation. J Inher Metab Dis 1995;18:473-490.
120. Taroni F, Uziel G. Fatty acid mitochondrial β-oxidation and hypoglycaemia in children. Curr Opin Neurol 1996:9:477-485.
121. Izai K, Uchida Y, Orii T, Yamamoto S, Hashimoto T. Novel fatty acid β-oxidation enzymes in rat liver mitochondria. I. Purification and properties of very-long chain acylcoenzyme A dehydrogenase. J Biol Chem 1992;267:1027-1033.
122. Uchida Y, Izai K, Orli T, Yamamoto T. Novel fatty acid β-oxidation enzymes in rat liver mitochondria. II. Purification and properties of enoyl-coenzyme A (CoA) hydratase/3-hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase trifunctional protein. J Biol Chem 1992;267:1034-1041.
123. Nada MA, Rhead WJ, Sprecher H, Schulz H, Roe CR. Evidence for intermediate channeling in mitochondrial β-oxidation. J Biol Chem 1995;270:530-535.
124. Oliver MF, Opie LH. Effect of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155-158.
125. Bremer J. Carnitine - metabolism and functions. Physiol Rev 1983;63:1420-1480.
126. Bohmer T, Eiklid K, Jonsen J. Carnitine uptake into human heart cells in culture. Biochim Biophys Acta 1977;465:627-634.
127. Chapoy PF, Angelini C, Brown WJ, Stiff JE, Shug A, Cederbaum SD. Systemic carnitine deficiency: a treatable inherited lipid storage disease presenting as Reye's syndrome. N Engl J Med 1980;303:1389-1394.
128. Tripp ME, Katcher ML, Peters HA, et al. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis. A treatable cardiomyopathy. N Engl J Med 1981;305:385-390.
129. Waber LJ, Valle D, Neill C, Di Mauro S, Shug A. Carnitine deficiency presenting as familial cardiomyopathy. A treatable defect in carnitine transport. J Pediatr 1982;101:700-705.
130. Stanley CA, De Leeuw S, Coates PM, et al. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol 1991;30:709-716.
131. Garavaglia B, Uziel G, Dworzak F, Carrara F, Di Donato S. Primary carnitine deficiency: heterozygote and intrafamilial phenotypic variation. Neurology 1991;41:1691-1693.
132. Eriksson BO, Lindstedt S, Nordin I. Hereditary defect in carnitine membrane transport is expressed in skin fibroblasts. Eur J Pediatr 1988;147:662-663.
133. Eriksson BO, Gustafson B, Lindstedt S, Nordin I. Transport of carnitine into cells in hereditary carnitine deficiency. J Inher Metab Dis 1989;12:108-111.
134. Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle and fibroblasts. N Engl J Med 1988;319:1331-1336.
135. Tein I, DeVivo DC, Bierman F, et al. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy. Pediatr Res 1990;28:247-255.
136. Bautista J, Rafel E, Martinez A, et al. Familial hypertrophic cardiomyopathy and muscle carnitine deficiency. Muscle Nerve 1990;13:192-194.
137. Stanley CA, Hale DE, Barry GT, Deleeuw S, Boxer J, Bonnefont JP. A deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med 1992;327:19-23.
138. Pande SV, Murthy MS. Carnitine-acylcarnitine translocase deficiency: implications in human pathology. Biochim Biophys Acta 1994;1226:269-276.
139. McGarry JD. The mitochondrial carnitine palmitoyltransferase system: its broadening role in fuel homeostasis and new insights into its molecular features. Biochem Soc Trans 1995;23:321-324.
140. Taroni F. Carnitine palmitoyltransferase deficiency. In: Gilman S, Goldstein GW, Waxman SG, editors. Neurobase, 1st ed. La Jolla: Arbor Publishing, 1995.
141. Taroni F, Verderio E, Dworzak F, Willems PJ, Cavadini P, Di Donato S. Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat Genet 1993;4:314-320.
142. Handig I, Dams E, Taroni F, van Laere S, de Barsy T, Willems PJ. Inheritance of the S113L mutation within an inbred family with carnitine palmitoyltransferase enzyme deficiency. Hum Genet 1996;97:291-293.
143. Bonnefont J-P, Taroni F, Cavadini P, et al. Molecular analysis of carnitine palmitoyltranferase II deficiency with hepatocardiomuscular expression. Am J Hum Genet 1996;58:971-978.
144. Verderio E, Cavadini P, Montermini L, et al. Carnitine palmitoyltransferase deficiency: structure of the gene and characterization of two novel disease-causing mutations. Hum Mol Genet 1995;4:19-29.
145. Taroni F, Verderio E, Fiorucci S, et al. Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. Proc Natl Acad Sci USA 1992;89:8429-8433.
146. Yamamoto S, Abe H, Kohgo T, et al. Two novel gene mutations (Glu174 → Lys, Phe383 → Tyr) causing the 'hepatic' form of carnitine palmitoyltransferase II deficiency. Hum Genet 1996;98:116-118.
147. Aoyama T, Souri M, Ushikubo S, et al. Purification of human very-long chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. J Clin Invest 1995;95:2465-2473.
148. Yamaguchi S, Indo Y, Coates PM, Hashimoto T, Tanaka K. Identification of very-long chain acyl-coenzyme A dehydrogenase deficiency in three patients previously diagnosed with long chain acyl-coenzyme A dehydrogenase deficiency. Pediatr Res 1993;34:111-113.
149. Bertrand C, Largilliere C, Zabot MT, Mathieu U, Vianey-Saban C. Very long chain acyl-CoA dehydrogenase deficiency: identification of a new inborn error of mitochondrial fatty acid oxidation in fibroblasts. Biochim Byophys Acta 1993;1180:327-329.
150. Merinero B, Perez-Cerda C, Garcia Silva MT, Vianey-Saban C, Duran M, Ugarte M. Mitochondrial very-long-chain acylCoA dehydrogenase deficiency with a mild clinical course. J Inher Metab Dis 1996;19:173-176.
151. Nada MA, Vianey-Saban C, Roe CR. Very-long chain acyl-CoA dehydrogenase deficiency: two phenotypes with distinctive biochemical findings. J Inher Metab Dis 1996;19:(suppl 1):53.
152. Aoyama T, Souri M, Ueno I, et al. Cloning of human very-long chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients. Am J Hum Genet 1995;57:273-283.
153. Strauss AW, Powell CK, Hale DE, et al. Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci USA 1995;92:10496-10500.
154. Souri M, Aoyama T, Orii K, Yamaguchi S, Hashimoto T. Mutation analysis of very-long chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency: identification and characterization of mutant VLCAD cDNAs from four patients. Am J Hum Genet 1996;59:97-106.
155. Andresen BS, Brosa P, Vianey-Saban C, et al. Cloning and characterization of human very-long-chain acyl-CoA dehydrogenase cDNA, chromosomal assignment of the gene and identification in four patients of nine different mutations within the VLCAD gene. Hum Mol Genet 1996;5:461-472.
156. Andresen BS, Vianey-Saban C, Brose P, et al. The mutational spectrum in very-long-chain acyl-CoA dehydrogenase deficiency. J Inher Metab Dis 1996;13:169-172.
157. Kelly DP, Mendelsohn NJ, Sobel BE, Bergmann S. Detection and assessment by positron emission tomography of a genetically deter-mined defect in myocardial fatty acid utilization (long-chain acyl-CoA dehydrogenase deficiency). Am J Cardiol 1993;71:738-744.
158. IJIst L, Wanders RJ, Ushikubo S, Kamijo T, Hashimoto T. Molecular basis of long-chain 3-hydroxyacyl-Coa dehydrogenase deficiency: identification of the major disease causing mutation in the alpha-subunit of the mitochondrial trifunctional protein. Biochim Biophys Acta 1994;1215:347-350.
159. Hagenfeldt L, Venizelos N, von Dobels U. Clinical and biochemical presentation of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J Inher Metab Dis 1995;18:245-248.
160. Pone R, Roig M, Riudor E, et al. The clinical spectrum of long-chain 3-hydroxyacyl-Coa dehydrogenase deficiency. Pediatr Neurol 1996;14:236-243.
161. Sims HE, Brackett JC, Powell CK, et al. The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci USA 1995;92:841-845.
162. IJIst L, Ushikubo S, Kamijo T, et al. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: high frequency of the G1528C mutation with no apparent correlation with the clinical phenotype. J Inher Metab Dis 1995;18:241-244.
163. IJIst L, Ruiter JPN, Vreijling J, Wanders RJA. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: a new method to identify the G1528C mutation in genomic DNA showing its high frequency and identification of a new mutation. J Inher Metab Dis 1996;19:165-168.
164. Ushikubo S, Aoyama T, Kamijo T, et al. Molecular characterization of mitochondrial trifunctional protein deficiency: formation of the enzyme complex is important for stabilization of both a-and β-subunits. Am J Hum Genet 1995;58:979-988.
165. Brackett JC, Sims HF, Rinaldo P, et al. Two α-subunit donor splice site mutations cause human trifunctional protein deficiency. J Clin Invest 1995;95:2076-2082.
166. Orii KE, Aoyama T, Souri M, et al. Formation of the enzyme complex is required for function of trifunctional β-oxidation protein. Biochem Biophys Res Commun 1996;219:773-777.
167. Loher JP, Goodman S, Frerman FE. Glutaric acidemia type II: heterogeneity of clinical and biochemical phenotypes. Pediatr Res 1900;27:311-315.
168. Bhala A, Willi SM, Rinaldo P, et al. Clinical and biochemical characterization of short-chain acylcoenzyme A dehydrogenase deficiency. J Pediatr 1995;126:910-915.
169. Iafolla AK, Thompson RJ, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 1994;124:409-415.
170. Hale DE, Batshaw W, Coates PM, et al. Long-chain acyl-coenzyme A dehydrogenase deficiency: an inherited cause of non-ketotic hypoglycemia. Pediatr Res 1985;19:666-671.
171. Bennet MJ, Weinberger MJ, Kobori JA, Rinaldo P, Burlina AB. Mitochondrial short-chain 1-3-hydroxyacyl-coenzyme A dehydrogenase deficiency: a new defect of fatty acid oxidation. Pediatr Res 1996;39:185-188.
172. Antozzi C, Garavaglia B, Mora M, et al. Late-onset riboflavin responsive myopathy with combined multiple acyl coenzyme A dehydrogenase and respiratory chain deficiency. Neurology 1994;44:2153-2158.
173. Przyrembel H. Therapy of mitochondrial disorders. J Inher Metab Dis 1987;10:129-146.
174. Walker UA, Byrne E. The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Acta Neurol Scand 1995;92:273-280.
175. Seibel P, Trappe J, Villani G, Klopstock T, Papa S, Reichmann H. Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA disorders. Nucleic Acids Res 1995;23:10-17.
176. MITOMAP: Human Mitochondrial Genome Database. Center for Molecular Medicine Emory University, Atlanta, GA, USA. World Wide Web (http://www.gen.emory.edu/mitomap.html), 1995.